Silence Therapeutics (SLN) EBT Margin: 2020-2025
Historic EBT Margin for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -13,180.50%.
- Silence Therapeutics' EBT Margin fell 1081101.00% to -13,180.50% in Q3 2025 from the same period last year, while for Sep 2025 it was -248.57%, marking a year-over-year increase of 11870.00%. This contributed to the annual value of -102.79% for FY2024, which is 6557.00% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' EBT Margin is -13,180.50%, which was down 7.97% from -12,207.14% recorded in Q2 2025.
- Silence Therapeutics' EBT Margin's 5-year high stood at 49.90% during Q4 2024, with a 5-year trough of -20,091.55% in Q1 2025.
- Moreover, its 3-year median value for EBT Margin was -713.01% (2023), whereas its average is -4,694.29%.
- Per our database at Business Quant, Silence Therapeutics' EBT Margin surged by 76,290bps in 2024 and then crashed by 2,007,838bps in 2025.
- Quarterly analysis of 5 years shows Silence Therapeutics' EBT Margin stood at -328.85% in 2021, then soared by 1,301bps to -315.84% in 2022, then tumbled by 39,716bps to -713.01% in 2023, then soared by 76,290bps to 49.90% in 2024, then tumbled by 1,081,101bps to -13,180.50% in 2025.
- Its last three reported values are -13,180.50% in Q3 2025, -12,207.14% for Q2 2025, and -20,091.55% during Q1 2025.